



NextPoint Therapeutics to Participate in the Leerink Partners Biopharma Private Company Connect

Cambridge, MA –October X, 2024 – [NextPoint Therapeutics](#), a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, today announced the company will participate in the Leerink Partners Biopharma Private Company Connect, which is being held virtually October 22-23. The company will be discussing its pipeline of programs harnessing the unique features of B7-H7 axis biology. B7-H7 is a novel tumor antigen that offers new hope for patients by acting both as a checkpoint pathway independent of PD-L1 as well as being an attractive tumor target for use in T cell engagers and antibody drug conjugates.

About NextPoint Therapeutics

NextPoint is launching a new world of precision immuno-oncology and tumor-targeting therapeutics through its leading scientific work on the novel B7-H7/HLA2 axis. Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed therapy, so that we can deliver a new class of monotherapies for patients. Our team of proven drug developers is simultaneously advancing therapeutic approaches blocking the B7-H7 immune signaling pathway and utilizing the unique upregulation of B7-H7 in cancer as an anchor for tumor-targeting treatment modalities. To learn more, visit nextpointtx.com.

Investor Contact:

Argot Partners

nextpoint@argotpartners.com